Kymera Therapeutics (NASDAQ:KYMR) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s stock price crossed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $114.90 and traded as high as $119.68. Kymera Therapeutics shares last traded at $117.57, with a volume of 827,856 shares traded.

Key Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: KT-579 produced encouraging Phase 1 results. Kymera reported deep and sustained IRF5 degradation, strong changes in disease-relevant biomarkers and a favorable safety profile in healthy volunteers. The data support continued development of KT-579 for immunological diseases and were the most important positive catalyst in the update. Kymera Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
• Positive Sentiment: BTIG Research raised its price target to $139 from $134 and maintained a Buy rating. The revised target implies approximately 13.4% potential upside based on the referenced share price, signaling continued analyst confidence in Kymera’s pipeline and outlook. BTIG Research Kymera Ratings
• Neutral Sentiment: Management’s Q3 earnings call focused on the KT-579 results and broader pipeline progress. Investors are likely looking for additional details on development plans, upcoming milestones and the company’s financial resources; the available transcript listings do not provide further quantified guidance. Kymera Q3 2026 Earnings Call Transcript
• Negative Sentiment: Quarterly results were weaker than expected. Kymera reported a third-quarter loss of $1.32 per share versus the $1.26 consensus estimate, while the year-ago loss was $0.94 per share. Revenue was essentially unchanged year over year, and the company continued to report a deeply negative net margin, underscoring its ongoing reliance on clinical development funding. Kymera Reports Third Quarter and Nine-Month Earnings Results

Wall Street Analyst Weigh In

Several equities analysts have issued reports on KYMR shares. Mizuho upped their price target on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the company an “outperform” rating in a research report on Thursday, July 16th. Wells Fargo & Company boosted their price objective on shares of Kymera Therapeutics from $116.00 to $151.00 and gave the stock an “overweight” rating in a research note on Thursday, August 27th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Kymera Therapeutics in a research note on Thursday, July 30th. They issued a “hold” rating and a $120.00 price objective on the stock. Wolfe Research upgraded Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $180.00 price objective for the company in a report on Thursday, September 10th. Finally, Stifel Nicolaus raised their target price on Kymera Therapeutics from $132.00 to $152.00 and gave the stock a “buy” rating in a research report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $137.32.

Kymera Therapeutics Stock Performance

The stock has a market cap of $10.19 billion, a P/E ratio of -37.84 and a beta of 1.98. The firm’s fifty day simple moving average is $114.83 and its 200-day simple moving average is $96.08.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, October 29th. The company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.06). Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.94) earnings per share. Analysts predict that Kymera Therapeutics, Inc. will post -3.85 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $113.80, for a total value of $3,414,000.00. Following the completion of the transaction, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at approximately $75,855,438.40. This trade represents a 4.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Brian Adams sold 6,371 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the completion of the transaction, the insider directly owned 50,254 shares in the company, valued at $5,871,174.82. This represents a 11.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 15.98% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Kymera Therapeutics in the 3rd quarter worth $514,000. China Universal Asset Management Co. Ltd. raised its holdings in Kymera Therapeutics by 20.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 15,812 shares of the company’s stock worth $1,747,000 after buying an additional 2,721 shares during the last quarter. Sterling Capital Management LLC lifted its stake in shares of Kymera Therapeutics by 378.6% in the third quarter. Sterling Capital Management LLC now owns 1,919 shares of the company’s stock valued at $215,000 after buying an additional 1,518 shares in the last quarter. Inspire Investing LLC bought a new position in shares of Kymera Therapeutics in the third quarter valued at $482,000. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Kymera Therapeutics by 45.9% in the third quarter. Nisa Investment Advisors LLC now owns 2,073 shares of the company’s stock valued at $232,000 after buying an additional 652 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.